Vanda Pharmaceuticals Inc. (VNDA)

21.11
NASDAQ : Health Technology
Prev Close 20.12
Day Low/High 19.70 / 21.14
52 Wk Low/High 13.88 / 33.44
Avg Volume 847.60K
Exchange NASDAQ
Shares Outstanding 52.45M
Market Cap 1.06B
EPS 0.50
P/E Ratio 83.83
Div & Yield N.A. (N.A)
Vanda Pharma FDA Panel Live Blog

Vanda Pharma FDA Panel Live Blog

An FDA panel will decide whether or not recommend the approval of Vanda's tasimelteon to treat a sleep disorder affecting blind people.

Today's Perilous Reversal Stock: Vanda Pharmaceuticals (VNDA)

Today's Perilous Reversal Stock: Vanda Pharmaceuticals (VNDA)

Trade-Ideas LLC identified Vanda Pharmaceuticals (VNDA) as a "perilous reversal" (up big yesterday but down big today) candidate

Barbarian At The Gate: Vanda Pharmaceuticals (VNDA)

Barbarian At The Gate: Vanda Pharmaceuticals (VNDA)

Trade-Ideas LLC identified Vanda Pharmaceuticals (VNDA) as a "barbarian at the gate" (strong stocks crossing above resistance with today's range greater than 200%) candidate

Interesting VNDA Put And Call Options For January 2016

Interesting VNDA Put And Call Options For January 2016

Investors in Vanda Pharmaceuticals Inc saw new options become available today, for the January 2016 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 795 days until expiration the newly available contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

VNDA January 2015 Options Begin Trading

VNDA January 2015 Options Begin Trading

Investors in Vanda Pharmaceuticals Inc saw new options become available today, for the January 2015 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 435 days until expiration the newly available contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Biotech Stock Mailbag: Vanda, Onconova, Catalyst Pharma, Sarepta

Biotech Stock Mailbag: Vanda, Onconova, Catalyst Pharma, Sarepta

Biotech columnist Adam Feuerstein answers readers' questions about health care companies.

Interesting VNDA Put And Call Options For June 2014

Interesting VNDA Put And Call Options For June 2014

Investors in Vanda Pharmaceuticals Inc saw new options begin trading this week, for the June 2014 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 241 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Vanda Pharmaceuticals Becomes Oversold (VNDA)

Vanda Pharmaceuticals Becomes Oversold (VNDA)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

5 Stocks Ready to Break Out

5 Stocks Ready to Break Out

These stocks look ready to break out and trade higher from current levels.

4 Biotech Stocks Triggering Breakout Trades

4 Biotech Stocks Triggering Breakout Trades

Keep thees biotech stocks trading on unusual volume on your radar.

UPCOMING DEADLINE: Levi & Korsinsky Notifies Investors With Losses On Their Investment In Vanda Pharmaceuticals, Inc. Of Class Action Lawsuit And The Deadline Of August 26, 2013 To Seek A Lead Plaintiff Position

UPCOMING DEADLINE: Levi & Korsinsky Notifies Investors With Losses On Their Investment In Vanda Pharmaceuticals, Inc. Of Class Action Lawsuit And The Deadline Of August 26, 2013 To Seek A Lead Plaintiff Position

Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the District of Columbia on behalf of investors who purchased Vanda Pharmaceuticals, Inc.

More Trouble for Vanda's Sleep Disorder Drug

More Trouble for Vanda's Sleep Disorder Drug

An analysis of the tasimelteon's phase III study is as troubling as the first.

5 Stocks Ready to Break Out

5 Stocks Ready to Break Out

These stocks look poised to break out and trade higher from current levels.

Vanda, FDA and $500K Bonus Paid to a Mystery Regulatory Consultant

Vanda, FDA and $500K Bonus Paid to a Mystery Regulatory Consultant

Why is Vanda spending a huge amount of money in cash bonuses to a consultant working to get its sleep disorder drug approved?

Short Interest Expands By 40.3% For VNDA

Short Interest Expands By 40.3% For VNDA

The most recent short interest data has been released by the NASDAQ for the 07/15/2013 settlement date, which shows a 1,018,126 share increase in total short interest for Vanda Pharmaceuticals Inc , to 3,547,106, an increase of 40.26% since 06/28/2013. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Biotech Stock Mailbag: GTx, Vanda, Pharmacyclics

Biotech Stock Mailbag: GTx, Vanda, Pharmacyclics

Biotech columnist Adam Feuerstein answers readers' questions about health care companies.

5 Stocks Setting Up to Break Out

5 Stocks Setting Up to Break Out

These stocks look ready to break out and trade higher from current levels.

Law Offices Of Todd M. Garber Announces Investigation Of Vanda Pharmaceuticals, Inc.

Law Offices Of Todd M. Garber Announces Investigation Of Vanda Pharmaceuticals, Inc.

The Law Offices of Todd M. Garber announces that it is investigating potential claims against Vanda Pharmaceuticals, Inc.

Vanda Pharmaceuticals Shareholder Alert: Briscoe Law And Powers Taylor Investigate Possible Breaches Of Fiduciary Duty By Officers And Directors

Vanda Pharmaceuticals Shareholder Alert: Briscoe Law And Powers Taylor Investigate Possible Breaches Of Fiduciary Duty By Officers And Directors

Former United States Securities and Exchange Commission attorney Willie Briscoe, founder of The Briscoe Law Firm, PLLC, and the securities litigation firm of Powers Taylor, LLP announce that a federal class action...

Best And Worst Performing Biotech Stocks In the Second Quarter

Best And Worst Performing Biotech Stocks In the Second Quarter

Clovis Oncology and Stemline Therapeutics were among the best-performing biotech stocks in the June quarter.

Washington, DC Law Firm Finkelstein Thompson LLP Investigates Vanda Pharmaceuticals, Inc.

Washington, DC Law Firm Finkelstein Thompson LLP Investigates Vanda Pharmaceuticals, Inc.

Shareholder law firm Finkelstein Thompson LLP is investigating potential claims on behalf of shareholders of Vanda Pharmaceuticals, Inc.

Biotech Stock Mailbag: PTC Therapeutics, Vanda, MannKind

Biotech Stock Mailbag: PTC Therapeutics, Vanda, MannKind

Biotech columnist Adam Feuerstein answers readers' questions about healthcare companies.

SHAREHOLDER ALERT: The Law Firm Of Levi & Korsinsky, LLP Launches An Investigation Into Possible Breaches Of Fiduciary Duty By Vanda Pharmaceuticals, Inc.

SHAREHOLDER ALERT: The Law Firm Of Levi & Korsinsky, LLP Launches An Investigation Into Possible Breaches Of Fiduciary Duty By Vanda Pharmaceuticals, Inc.

Levi & Korsinsky is investigating potential claims on behalf of purchasers of Vanda Pharmaceuticals, Inc.

Law Firm Of Wohl & Fruchter LLP Announces Investigation Of Vanda Pharmaceuticals, Inc.

Law Firm Of Wohl & Fruchter LLP Announces Investigation Of Vanda Pharmaceuticals, Inc.

The law firm of Wohl & Fruchter LLP announces that it is investigating possible violations of federal securities laws by officers and directors of Vanda Pharmaceuticals, Inc.

Stock Futures Waver as Investors Go On Bernanke-Watch

Stock Futures Waver as Investors Go On Bernanke-Watch

Stock futures are wavering Wednesday as investors eagerly await the conclusion of the two-day Federal Reserve meeting.

Vanda's Sleep Disorder Drug Is A Nightmare

Vanda's Sleep Disorder Drug Is A Nightmare

FDA approval of tasimelteon is unlikely because Vanda changed the study design and mis-enrolled patients.

Raise Cash Ahead of Fed News

The market could take off on a bullish surprise, but binary events are always tough to trade.

Commit To Purchase Vanda Pharmaceuticals At $7, Earn 21.1% Annualized

Commit To Purchase Vanda Pharmaceuticals At $7, Earn 21.1% Annualized

Investors eyeing a purchase of Vanda Pharmaceuticals Inc shares, but cautious about paying the going market price of $9.27/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the December put at the $7 strike, which has a bid at the time of this writing of 80 cents.

TheStreet Quant Rating: C+ (Hold)